Vontobel Holding Ltd. Has $4.60 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vontobel Holding Ltd. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 6,458 shares of the biopharmaceutical company’s stock after acquiring an additional 2,322 shares during the period. Vontobel Holding Ltd.’s holdings in Regeneron Pharmaceuticals were worth $4,600,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Asset Management One Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 6.2% during the fourth quarter. Asset Management One Co. Ltd. now owns 59,980 shares of the biopharmaceutical company’s stock worth $42,730,000 after purchasing an additional 3,504 shares during the last quarter. Avestar Capital LLC boosted its holdings in Regeneron Pharmaceuticals by 8.9% during the fourth quarter. Avestar Capital LLC now owns 787 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 64 shares during the last quarter. Hemington Wealth Management boosted its holdings in Regeneron Pharmaceuticals by 28.7% during the fourth quarter. Hemington Wealth Management now owns 121 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 27 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Regeneron Pharmaceuticals by 0.7% during the fourth quarter. Van ECK Associates Corp now owns 58,533 shares of the biopharmaceutical company’s stock worth $41,694,000 after purchasing an additional 397 shares during the last quarter. Finally, Legato Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 10.0% during the fourth quarter. Legato Capital Management LLC now owns 4,507 shares of the biopharmaceutical company’s stock worth $3,210,000 after purchasing an additional 411 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

REGN opened at $673.60 on Friday. The company’s 50 day moving average is $706.92 and its 200-day moving average is $897.42. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $74.02 billion, a P/E ratio of 17.60, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.